We are 224,420 members in 82 forums discussing 157,745 topics.

Help with Abbreviations

Topic: Breastcancer.org Podcasts: Listen to Experts Discuss

Forum: Mod Announcements, Breastcancer.org News, Blog Entries, Podcasts —

Moderator generated forum to present our announcements or requests, organization and website news, blog entries and podcasts. Please do not post here if you are not a Moderator. Thank you!

Posted on: Dec 12, 2013 10:28AM - edited Oct 5, 2014 02:45PM by Moderators

Moderators wrote:

Please go here to read about and listen to all our Podcasts! We will also be posting podcasts below as they air.

Note: Podcasts will be available in transcript form about 24 - 48 hours after the Podcasts have aired.

To send a Private Message to the Mods: community.breastcancer.org/mem...
Log in to post a reply

Page 6 of 6 (160 results)

Posts 151 - 160 (160 total)

Log in to post a reply

Oct 1, 2019 12:10PM Moderators wrote:

Where Are We With Immunotherapy for Breast Cancer? ESMO 2019 Coverage

September 27, 2019

Litton jennifer

Dr. Jennifer Litton is a board certified medical oncologist and professor of breast medical oncology at the University of Texas MD Anderson Cancer Center in Houston, where she is chief of the Section of Clinical Research and Drug Development for Breast Cancer. She also is a member of the Breast Immuno-Oncology Task Force of the National Cancer Institute.

At the European Society for Medical Oncology 2019 Congress, she presented information on a study she's leading, looking at combining a new type of immunotherapy with a traditional chemotherapy medicine. She joined us to talk about current immunotherapy research for breast cancer in general as well as what is specifically being presented at the congress.

Listen to the podcast to hear Dr. Litton discuss:

  • why immunotherapy medicines to treat breast cancer will likely be used with another type of therapy, such as chemotherapy or radiation therapy
  • the difference between a "hot" and "cold" tumor and why that is important for immunotherapy
  • other biomarkers besides PD-L1 that may help doctors decided if an immunotherapy medicine will work

Running time: 16:50

Listen now or read the transcript.

To send a Private Message to the Mods: community.breastcancer.org/mem...
Log in to post a reply

Oct 1, 2019 12:11PM Moderators wrote:

People Satisfied With Decision to Use Scalp Cooling, Even If It's Not Effective -- Heard in the Halls: Voices From ESMO 2019

September 28, 2019

Murphy

Dr. Conleth Murphy, an oncologist at Bon Secours Cork Cancer Center in Ireland, discusses his research on scalp cooling in people being treated with chemotherapy for cancer.

Running time: 2:58

Listen now or read the transcript.

To send a Private Message to the Mods: community.breastcancer.org/mem...
Log in to post a reply

Oct 1, 2019 12:11PM Moderators wrote:

Immunotherapy to Treat Metastatic HER2-Positive Breast Cancer: ESMO 2019 Coverage

September 29, 2019

Emens leisha

Dr. Leisha Emens is professor of medicine in hematology/oncology at the University of Pittsburgh Hillman Cancer Center. She is also co-leader of the Hillman Cancer Immunology and Immunotherapy Program and director of translational immunotherapy for the Women's Cancer Research Center. She is internationally recognized for her work in breast cancer immunotherapy.

At the European Society for Medical Oncology 2019 Congress, she presented overall survival results from the KATE2 study, which compared using the combination of Tecentriq, also called atezolizumab, and Kadcyla, also called T-DM1, to Kadcyla alone to treat HER2-positive metastatic breast cancer that had grown while being treated with Herceptin and chemotherapy.

Listen to the podcast to hear Dr. Emens discuss:

  • the design of the KATE2 study
  • why the study is encouraging, even though it didn't meet its primary endpoint
  • what the results mean for people diagnosed with HER2-positive metastatic breast cancer
  • her advice to people diagnosed with breast cancer who are interested in immunotherapy

Running time: 10:04

Listen now or read the transcript.

To send a Private Message to the Mods: community.breastcancer.org/mem...
Log in to post a reply

Oct 1, 2019 12:11PM Moderators wrote:

Immunotherapy Keytruda for Early-Stage Triple-Negative Breast Cancer: Better pCR and Lower Recurrence Rates: ESMO 2019 Coverage

September 29, 2019

Schmid peter

Dr. Peter Schmid is chair in cancer medicine at Barts Cancer Institute, Queen Mary University London and also serves as clinical director of the Breast Cancer Centre at the St. Bartholomew Cancer Centre and honorary consultant medical oncologist at Barts Hospital. His research focuses on breast cancer, cancer immune therapy, and early drug development.

At the European Society for Medical Oncology 2019 Congress, he presented results from the KEYNOTE-522 study showing that the combination of the immunotherapy Keytruda (chemical name: pembrolizumab) and chemotherapy before surgery to remove early-stage triple-negative breast cancer led to a better pathologic complete response than chemotherapy alone. This is the first phase III study using immunotherapy to treat early-stage breast cancer.

Listen to the podcast to hear Dr. Schmid discuss:

  • the design of the KEYNOTE-522 study
  • side effects related to both chemotherapy and Keytruda
  • what these results mean for patients

Running time: 9:27

Listen now or read the transcript.

To send a Private Message to the Mods: community.breastcancer.org/mem...
Log in to post a reply

Oct 1, 2019 12:12PM Moderators wrote:

"CDK4/6 Inhibitor Plus Hormonal Therapy Should Be First Treatment for Metastatic Hormone-Receptor-Positive, HER2-Negative Breast Cancer" ESMO 2019 Coverage

September 29, 2019

Slamon dennis

Dr. Dennis Slamon is professor of medicine and executive vice chair for research for the UCLA Department of Medicine. He also serves as director of clinical/translational research and director of the Revlon/UCLA Women's Cancer Research Program at the Jonsson Comprehensive Cancer Center at UCLA. He is probably best known for doing the laboratory and clinical research that led to the development of Herceptin, the first medicine to specifically treat HER2-positive breast cancer. Dr. Slamon has won numerous awards for his research. Earlier this month, he received the 2019 Lasker Award for clinical medical research for his groundbreaking work on Herceptin.

At the European Society for Medical Oncology 2019 Congress, he presented overall survival results from the MONALEESA-3 study, looking at using the CDK4/6 inhibitor Kisqali (chemical name: ribociclib) plus the hormonal therapy Faslodex (chemical name: fulvestrant) to treat advanced-stage, hormone-receptor-positive, HER2-negative breast cancer in postmenopausal women.

Listen to the podcast to hear Dr. Slamon explain:

  • the background of the MONALEESA-3 study
  • how much adding Kisqali to Faslodex improved overall survival compared to Faslodex alone
  • treatment side effects seen in the study
  • what the results mean for people diagnosed with metastatic hormone-receptor-positive, HER2-negative breast cancer

Running time: 9:10

Listen now or read the transcript.

To send a Private Message to the Mods: community.breastcancer.org/mem...
Log in to post a reply

Oct 1, 2019 12:12PM Moderators wrote:

Breast Cancer Research Highlights -- Heard in the Halls: Voices From ESMO 2019

September 29, 2019

White anne

Anne White, president of Lilly Oncology, discusses some of the most talked about breast cancer research presented at ESMO 2019.

Running time: 10:40

Listen now or read the transcript.

To send a Private Message to the Mods: community.breastcancer.org/mem...
Log in to post a reply

Oct 1, 2019 12:12PM Moderators wrote:

Verzenio Plus Faslodex Improves Survival in Metastatic Hormone-Receptor-Positive, HER2-Negative Breast Cancer, Regardless of Menopausal Status

September 29, 2019

Sledge george

Dr. George Sledge is professor of medicine and head of the Oncology Division at Stanford University. A former president of the American Society of Clinical Oncology, he specializes in breast cancer research. He has published extensively on the treatment of metastatic breast cancer and has been honored with numerous awards for his work.

At the European Society for Medical Oncology 2019 Congress, he presented overall survival results from the MONARCH 2 study, which used Verzenio (chemical name: abemaciclib) and Faslodex (chemical name: fulvestrant) to treat metastatic hormone-receptor-positive, HER2-negative breast cancer that was previously treated with hormonal therapy and had stopped responding. The women in the study were premenopausal, perimenopausal, or postmenopausal.

Listen to the podcast to hear Dr. Sledge explain:

  • the background of the MONARCH 2 study
  • how much overall survival was improved
  • the side effects seen in the study
  • what the results mean for people diagnosed with metastatic hormone-receptor-positive, HER2-negative breast cancer

Running time: 6:45

LIsten now or read the transcript.

To send a Private Message to the Mods: community.breastcancer.org/mem...
Log in to post a reply

Oct 23, 2019 12:11PM Moderators wrote:

How to Ease Aromatase Inhibitor-Related Pain

October 4, 2019

Khanna ashish

Ashish Khanna, M.D., is a physical medicine and rehabilitation specialist at the Kessler Institute for Rehabilitation and part of the ReVital Cancer Rehabilitation Program. Dr. Khanna completed his residency in physical medicine and rehabilitation at the Kingsbrook Jewish Rehabilitation Institute in Brooklyn, NY, where he became interested in cancer rehabilitation early on. He completed his fellowship subspecialization in cancer rehabilitation at Medstar Georgetown University and the National Rehabilitation Hospital in Washington, DC. He specializes in the treatment of people who have pain or functional issues as a result of cancer or cancer treatments, including people who have been diagnosed with breast cancer. This includes pain, shoulder issues, fatigue, joint pain from aromatase inhibitors, and other issues. He has lectured at numerous international conferences, has published peer-reviewed research on a variety of related topics, and is the co-author of an upcoming book on cancer rehabilitation.

Listen to the podcast to hear Dr. Khanna discuss:

  • what aromatase inhibitors are and how they treat hormone-receptor-positive breast cancer
  • why and how aromatase inhibitors cause joint pain
  • how exercise can reduce aromatase inhibitor-related joint pain
  • other ways to ease this joint pain

Running time: 22:56

Listen now or read the transcript.

To send a Private Message to the Mods: community.breastcancer.org/mem...
Log in to post a reply

Oct 30, 2019 02:17PM - edited Nov 12, 2019 01:57PM by Moderators

Characteristics of Early-Stage Breast Cancer That Make It More Likely to Come Back

October 25, 2019

Shah chirag

Dr. Chirag Shah is a radiation oncologist and director of clinical research for the department of radiation oncology at the Cleveland Clinic. Dr. Shah received his bachelor's degree from Youngstown State University and his medical degree from Northeast Ohio Medical University. He completed his internship and residency at William Beaumont Hospital from 2007 to 2012 and joined the Cleveland Clinic Staff in 2015. Dr. Shah serves as a reviewer for various medical journals and is a member of various medical societies. His primary research interests are breast cancer, sarcoma, prostate cancer, lymphoma, and innovative radiation treatment schedules as well as lymphedema. He has participated in numerous clinical trials.

In this podcast, Dr. Shah talks about specific characteristics of early-stage breast cancer that make the cancer more likely to come back, which doctors call recurrence, as well as what can be done to lower that risk.

Listen to the podcast to hear Dr. Shah discuss:

  • the difference between local/regional recurrence and metastatic/distant recurrence
  • the characteristics of early-stage breast cancer that make the risk of recurrence higher

Running time: 15:28

Listen now or read the transcript.
To send a Private Message to the Mods: community.breastcancer.org/mem...
Log in to post a reply

Nov 12, 2019 01:57PM Moderators wrote:

Sharing Knowledge: Pairing Experts With Patient Advocates

November 8, 2019

Hodgdon christine

Christine Hodgdon was diagnosed with de novo metastatic breast cancer in April 2015 and became heavily involved in the metastatic community after attending a Metavivor advocacy event on Capitol Hill to push for more research funding for metastatic breast cancer.

Christine volunteers with a number of breast cancer organizations, including Living Beyond Breast Cancer, METAvivor, and the Tigerlily Foundation. She also has contributed articles and blogs to organizations to raise awareness of metastatic breast cancer and serves as a peer mentor for the Young Survival Coalition.

Before she was diagnosed, Christine loved to travel and was a Peace Corps volunteer in Guatemala from 2011-2013. When she returned, she worked as a conservation biologist to save habitat for endangered species. Now Christine is using her science background to create an open-access online forum thestormriders.org that provides the most recent and scientifically accurate information about breast cancer and its treatments, including metastatic breast cancer clinical trials and drugs and therapies in the pipeline. She also has created a pilot program, pairing oncology experts with new patient advocates at the San Antonio Breast Cancer Symposium, which is what we talk about during this podcast.

Listen to the podcast to hear Christine talk about:

  • how the cancer diagnoses changed her
  • how she keeps up with breast cancer research
  • her pilot program to pair oncology experts and patient advocates at the San Antonio Breast Cancer Symposium
  • what she wants people to know about metastatic breast cancer

Running time: 28:33

Listen now or read the transcript.

To send a Private Message to the Mods: community.breastcancer.org/mem...

Page 6 of 6 (160 results)